Home » Archives by category » Pharma Industry News

Finch secures $53m to advance microbiome therapies for CDI, Autism

Finch secures $53m to advance microbiome therapies for CDI, Autism

Finch Therapeutics, a US microbiome therapeutics company, has raised $53 million through a Series C financing round to advance its pipeline of microbial therapies, as per the latest pharma industry news. In addition to existing investors Avenir Growth Capital, Morgan Noble, Shumway Capital, and Willett Advisors, the funding for the US microbiome therapeutics company has […]

The post Finch secures $53m to advance microbiome therapies for CDI, Autism appeared first on PharmaNewsDaily.com.

Pfizer to build $500m gene therapy manufacturing facility in Sanford

Pfizer to build $500m gene therapy manufacturing facility in Sanford

US pharma giant Pfizer has committed $500 million to expand its gene therapy by constructing a new gene therapy manufacturing facility in Sanford in North Carolina. Pfizer’s Sanford gene therapy facility will expand the company’s manufacturing footprint in North Carolina and help advance production of one-time gene therapies that use custom-made recombinant adeno-associated virus (rAAV) […]

The post Pfizer to build $500m gene therapy manufacturing facility in Sanford appeared first on PharmaNewsDaily.com.

US pharma manufacturer Conagen acquires glycoproteins production platform

US pharma manufacturer Conagen acquires glycoproteins production platform

US pharma manufacturer Conagen has purchased a glycoproteins production platform – a fermentation-based technology for the production of glycoproteins used for making therapeutics, for an undisclosed price. The acquisition made from an undisclosed seller includes various patents covering the glycoproteins production platform and all related tangible assets, which are expected to place Conagen among the […]

The post US pharma manufacturer Conagen acquires glycoproteins production platform appeared first on PharmaNewsDaily.com.

Bayer to divest animal health business to Elanco for $7.6bn

Bayer to divest animal health business to Elanco for $7.6bn

US-based veterinary pharmaceuticals producer Elanco Animal Health has agreed to acquire German drug giant Bayer’s animal health business for $7.6 billion, financed by a combination of 70% cash and 30% equity. The transaction, which enhances emerging market presence and strengthens cattle business, will strengthen Elanco’s Innovation, Portfolio, and Productivity (IPP) strategy, creating the second largest […]

The post Bayer to divest animal health business to Elanco for $7.6bn appeared first on PharmaNewsDaily.com.

Eiger bags FDA breakthrough therapy status for HDV drug candidate Lambda

Eiger bags FDA breakthrough therapy status for HDV drug candidate Lambda

US biopharma company Eiger BioPharmaceuticals said that peginterferon lambda (Lambda) has been granted breakthrough therapy designation from the US Food and Drug Administration (FDA) for the treatment of hepatitis delta virus (HDV) infection. Breakthrough therapy designation enables expedition of the development and review of drugs intended for the treatment of a serious condition and where […]

The post Eiger bags FDA breakthrough therapy status for HDV drug candidate Lambda appeared first on PharmaNewsDaily.com.

NKMax America launches SNK01-MX03 clinical trial in plaque psoriasis

NKMax America launches SNK01-MX03 clinical trial in plaque psoriasis

SNK01-MX03 clinical trial : NKMax America, a US biotech company, has initiated a phase 1 trial called SNK01-MX03 to investigate its ex vivo expanded autologous natural killer cell therapeutic SNK in plaque psoriasis. In this connection, NKMax America treated the first patient in the SNK01-MX03 clinical trial, which is a single center, dose-escalation study for […]

The post NKMax America launches SNK01-MX03 clinical trial in plaque psoriasis appeared first on PharmaNewsDaily.com.

Mexican pharma company Sanfer secures $500m investment from CDPQ

Mexican pharma company Sanfer secures $500m investment from CDPQ

CDPQ investment in Sanfer : Mexican pharma company Sanfer has secured a $500 million minority investment from Canadian long-term institutional investor Caisse de dépôt et placement du Québec (CDPQ) to help it execute its continued expansion plans across Mexico and the Latin American region. In the last 20 years, Sanfer claims to have closed more than […]

The post Mexican pharma company Sanfer secures $500m investment from CDPQ appeared first on PharmaNewsDaily.com.

Nabriva secures Xenleta FDA approval for community-acquired pneumonia

Nabriva secures Xenleta FDA approval for community-acquired pneumonia

Xenleta FDA approval : Irish pharma company Nabriva Therapeutics has bagged approval from the US Food and Drug Administration for its semi-synthetic pleuromutilin antibiotic Xenleta (lefamulin) for the treatment of community-acquired bacterial pneumonia in adults. Community-acquired pneumonia is caused when someone develops pneumonia in the community, that is not in a hospital. Pneumonia is a […]

The post Nabriva secures Xenleta FDA approval for community-acquired pneumonia appeared first on PharmaNewsDaily.com.

Celgene bags Inrebic FDA approval for myelofibrosis

Celgene bags Inrebic FDA approval for myelofibrosis

Inrebic FDA approval : Celgene’s subsidiary Impact Biomedicines, has bagged approval for its oral kinase inhibitor Inrebic (fedratinib) capsules from the US Food and Drug Administration (FDA) for the treatment of certain types of myelofibrosis, a rare bone marrow cancer. Fedratinib FDA approval is for the treatment of adult patients with intermediate-2 or high-risk primary […]

The post Celgene bags Inrebic FDA approval for myelofibrosis appeared first on PharmaNewsDaily.com.

Alfasigma USA launches IBS-C drug ZELNORM in US

Alfasigma USA launches IBS-C drug ZELNORM in US

Alfasigma USA has launched ZELNORM (tegaserod) tablets in the US as a prescription drug for irritable bowel syndrome with constipation (IBS-C) in adult women aged under 65 years. ZELNORM was acquired by Alfasigma USA in July 2019 from Sloan Pharma, a subsidiary of US WorldMeds. Bryan Downey – president and CEO of Alfasigma USA said: “We […]

The post Alfasigma USA launches IBS-C drug ZELNORM in US appeared first on PharmaNewsDaily.com.


Notice: Undefined variable: additional_loop in /var/www/wp-content/themes/_connect/archive-default.php on line 10

Notice: Trying to get property of non-object in /var/www/wp-content/themes/_connect/archive-default.php on line 10
Page 1 of 512345